Psychedelic Therapeutics & Drug Development

The 3rd Annual Psychedelic Therapeutics & Drug Development Conference, May 15-16, 2023, in the San Francisco Bay Area, builds on the success of its previous editions by bringing together leading researchers, academics, industry professionals, non-profit organizations, and government representatives. The event focuses on the challenges and opportunities in researching and developing psychedelics for various health conditions with considerable unmet needs.

Participants can look forward to insightful discussions highlighting the progress towards regulatory approval of various psychedelic substances with the potential to treat conditions such as inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.

Featuring a lineup of expert speakers and panellists, the conference covers crucial topics, including clinical trial design, intellectual property, regulatory guidance, psychedelic drug delivery, commercialization, legal issues, emerging preclinical science, and new clinical data, among others. The event is meticulously curated to provide practical guidance, foster discussion, and facilitate networking opportunities for key stakeholders in this rapidly growing field.

By uniting the brightest minds and fostering interdisciplinary dialogue, the 3rd Annual Psychedelic Therapeutics & Drug Development Conference aims to accelerate advancements in psychedelic research, therapy, and policy, ultimately contributing to the responsible development and integration of these transformative medicines.

Speakers for the 2023 conference include Joshua Woolley, Boris Heifets and Gul Dolen.